Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting semaglutide using G2GBIO's proprietary microsphere technology -- Epis NexLab, a sister ...
Boston Scientific announced FDA clearance for the “Any Day Dosing” feature on the company’s TheraSphere 360 ytt ...
Samsung Bioepis will be given a full license right for the novel long-acting semaglutide asset, and an option to license another asset from G2GBIO.
Samsung Bioepis and Epis NexLab, subsidiaries of Samsung Epis Holdings, have signed a joint research and licensing agreement ...
More than 10,000 Americans are waiting for a liver transplant. Many more never make the list, because they are too sick to ...
Samsung Bioepis and Epis NexLab ink research collaboration and license pact with G2GBIO to develop novel assets including long-acting semaglutide: Incheon, Korea Tuesday, March 17 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results